Skip to main content

Advertisement

Table 1 Studies included in meta-analysis

From: Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia

First author, year Study type No. of patients Mean onabotA dose/injection Duration of effect Definition of duration Country of origin
Mean (±SD) units Mean (±SD)
Benecke 2005 [17] Prospective, randomized, double-blind, parallel-group, noninferiority study 232 138.9 ± 46.8 94.3 ± 31.4 days Interval between injection and first visit at which TWSTRS severity score reached 80% of baseline Ex-US
Bihari 2005 [6] Prospective, single-arm, crossover study 12a 131 64.3 days Time to reach 70% TWSTRS score Ex-US
Brashear 2005 [3] Retrospective 172b 241.80-254.07 108.48 days (year 1) Interval between treatments US
Brashear 2000 [25] Retrospective 60 263 15.5 ± 3.4 weeks Interval between visits US
Brashear 1998 [27] Prospective, single-center study 149c 219.8 ± 63.5 142.9 ± 85.8 days Average time between treatments US
Brin 2008 [29] Prospective, open-label, multicenter study 326 187.0 ± 76.5 110.2 ± 91.8 days Time from treatment injection to date of next injection US/Ex-US
Brockmann 2012 [24] Retrospective 20 175 ± 76 10.7 ± 1.9 weeks Time between last treatment and first subjective notice of reduction of benefit from the treatment Ex-US
Camargo 2008 [18] Prospective, single-center study 85 151.05 ± 52.55 89.1 ± 21.8 days Patient-reported time to return of symptoms Ex-US
Dubinsky 1991 [28] Prospective cohort 84 269 ± 39 107 ± 49 days Time from initial injection until patient-reported worsening of symptoms US
Jankovic 2003 [19] Prospective, single-center study 119 223.9 ± 73.0 14.6 ± 5.6 weeks Not specified US
Jankovic 1990 [26] Prospective cohort 205 105.4 ± 33.8 14.0 ± 6.9 weeks Duration of peak effect US
Maia 2010 [20] Retrospective 67 204.79 13.01 weeks Duration which patient had any benefit from treatment Ex-US
Meija 2005 [21] Retrospective 16d 221.2 ± 129.4 15.4 ± 3.4 weeks Not specified US
Mohammadi 2009 [7] Prospective cohort 44 145 ± 44 10 ± 2.4 weeks Not specified Ex-US
Naumann 2002 [8] Prospective, randomized, double-blind, crossover study 59 155 ± 51 13.9 ± 2.6 weeks Time to TWSTRS severity score ≥10 and rotational score ≥1 Ex-US
68 157 ± 44 13.6 ± 2.4 weeks
Odergren 1998 [22] Prospective, randomized, double-blind, parallel-group study 35 152 ± 45 80.7 ± 14.4 days Time to retreatment Ex-US
Quagliato 2010 [30] Prospective, randomized, double-blind study 12e NR 11.7 ± 3.4 weeks Interval between day of treatment and patient-reported waning effect Ex-US
Ranoux 2002 [23] Prospective, randomized, double-blind, crossover study 51 104.4 ± 20.6 89.1 ± 19 days Interval between day of treatment and patient-reported waning of effect Ex-US
  1. a48 total patients; only 12 had CD. bCase report forms. c156 total patients; 149 had idiopathic CD. d45 total patients; 16 had CD. e24 total patients; 12 received onabotulinumtoxinA.
  2. Abbreviations: NR not reported, onabotA onabotulinumtoxinA, TWSTRS Toronto Western Spasmodic Torticollis Rating Scale.